Advanced cell programming

An extensive cell programing capability

Engineered T cell immunotherapy products show significant efficacy for hematological malignancies

However, realization of the potential of this approach across a broad range of tumor types will require multiple technology solutions to address limitations of the current generation of therapies.

Our technological approach is the development of advanced T-cell engineering components designed to directly address clinical challenges. A focus in our early stage pipeline is incorporation of multiple components in a single product.

Latest Abstracts & Publications

See all
American Society of Hematology Annual Meeting
December 13 2021

Safety and Efficacy of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL) and Chronic Lymphocytic Leukaemia (CLL)

Obe-cel
Fast off rate CAR
American Society of Hematology Annual Meeting
December 12 2021

Industrialization of an Academic Miltenyi Prodigy-Based CAR T process

Obe-cel
Fast off rate CAR
American Society of Hematology Annual Meeting
December 11 2021

A high sensitivity aCD22 CAR combined with aCD19 CAR to generate dual targeting CAR T cells for the treatment of r/r B-ALL

AUTO1/22
Fast off rate CAR
Dual targeting CAR